Pontifax Management 4 G.P. (2015) Ltd. Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Pontifax Management 4 G.P. (2015) Ltd..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Pontifax Management 4 G.P. (2015) Ltd.. Pontifax Management 4 G.P. (2015) Ltd. is in Eloxx Pharmaceuticals, Inc. ($ELOX) and 10% Owner in Eloxx Pharmaceuticals, Inc. ($ELOX) and 10% Owner in Keros Therapeutics, Inc. ($KROS).
Latest Insider Trading Transactions of Pontifax Management 4 G.P. (2015) Ltd.
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 17 2021 | ELOX | Eloxx Pharmaceutic ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | P | 1.35 | 592,592 | 799,999 | 616,592 | 24 K to 616.6 K (+2,469.13 %) |
| May 17 2021 | ELOX | Eloxx Pharmaceutic ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | P | 1.35 | 1,422,222 | 1,920,000 | 1,989,551 | 567.3 K to 2 M (+250.69 %) |
| May 17 2021 | ELOX | Eloxx Pharmaceutic ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | P | 1.35 | 2,630,487 | 3,551,157 | 3,679,797 | 1 M to 3.7 M (+250.69 %) |
| May 17 2021 | ELOX | Eloxx Pharmaceutic ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | P | 1.35 | 1,280,624 | 1,728,842 | 1,791,470 | 510.8 K to 1.8 M (+250.69 %) |
| Nov 19 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | P | 50.00 | 6,000 | 300,000 | 155,262 | 149.3 K to 155.3 K (+4.02 %) |
| Nov 19 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | P | 50.00 | 14,400 | 720,000 | 1,228,326 | 1.2 M to 1.2 M (+1.19 %) |
| Nov 19 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | P | 50.00 | 12,966 | 648,300 | 1,122,768 | 1.1 M to 1.1 M (+1.17 %) |
| Nov 19 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | P | 50.00 | 26,634 | 1,331,700 | 2,288,151 | 2.3 M to 2.3 M (+1.18 %) |
| May 22 2020 | ELOX | Eloxx Pharmaceutic ... | Pontifax Management 4 G.P. (20 ... | Option Exercise | A | 3.39 | 20,000 | 67,800 | 20,000 | ||
| May 22 2020 | ELOX | Eloxx Pharmaceutic ... | Pontifax Management 4 G.P. (20 ... | Option Exercise | A | 3.39 | 20,000 | 67,800 | 20,000 | ||
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Option Exercise | C | 0.00 | 36,858 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Option Exercise | C | 0.00 | 79,653 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Option Exercise | C | 0.00 | 88,460 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Option Exercise | C | 0.00 | 163,612 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Option Exercise | C | 0.00 | 68,654 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Option Exercise | C | 0.00 | 91,538 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Option Exercise | C | 0.00 | 82,425 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Option Exercise | C | 0.00 | 169,307 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Option Exercise | C | 0.00 | 737,226 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Option Exercise | C | 0.00 | 663,825 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Option Exercise | C | 0.00 | 1,363,542 | 0 | 0 | |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | P | 16.00 | 43,750 | 700,000 | 149,262 | 105.5 K to 149.3 K (+41.46 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | P | 16.00 | 105,000 | 1,680,000 | 1,213,926 | 1.1 M to 1.2 M (+9.47 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | P | 16.00 | 94,546 | 1,512,736 | 1,109,802 | 1 M to 1.1 M (+9.31 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | P | 16.00 | 194,203 | 3,107,248 | 2,261,517 | 2.1 M to 2.3 M (+9.39 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | C | 0.00 | 36,858 | 0 | 105,512 | 68.7 K to 105.5 K (+53.69 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | C | 0.00 | 79,653 | 0 | 1,108,926 | 1 M to 1.1 M (+7.74 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | C | 0.00 | 88,460 | 0 | 1,015,256 | 926.8 K to 1 M (+9.54 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | C | 0.00 | 163,612 | 0 | 2,067,314 | 1.9 M to 2.1 M (+8.59 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | C | 0.00 | 68,654 | 0 | 68,654 | 0 to 68.7 K |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | C | 0.00 | 91,538 | 0 | 1,029,273 | 937.7 K to 1 M (+9.76 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | C | 0.00 | 82,425 | 0 | 926,796 | 844.4 K to 926.8 K (+9.76 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | C | 0.00 | 169,307 | 0 | 1,903,702 | 1.7 M to 1.9 M (+9.76 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | C | 0.00 | 737,226 | 0 | 937,735 | 200.5 K to 937.7 K (+367.68 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | C | 0.00 | 663,825 | 0 | 844,371 | 180.5 K to 844.4 K (+367.68 %) |
| Apr 13 2020 | KROS | Keros Therapeutics ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | C | 0.00 | 1,363,542 | 0 | 1,734,395 | 370.9 K to 1.7 M (+367.68 %) |
| Jun 26 2019 | ELOX | Eloxx Pharmaceutic ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | P | 9.00 | 24,000 | 216,000 | 24,000 | 0 to 24 K |
| Jun 26 2019 | ELOX | Eloxx Pharmaceutic ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | P | 9.00 | 46,933 | 422,397 | 567,329 | 520.4 K to 567.3 K (+9.02 %) |
| Jun 26 2019 | ELOX | Eloxx Pharmaceutic ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | P | 9.00 | 86,806 | 781,254 | 1,049,310 | 962.5 K to 1 M (+9.02 %) |
| Jun 26 2019 | ELOX | Eloxx Pharmaceutic ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | P | 9.00 | 42,261 | 380,349 | 510,846 | 468.6 K to 510.8 K (+9.02 %) |
| May 29 2019 | ELOX | Eloxx Pharmaceutic ... | Pontifax Management 4 G.P. (20 ... | Option Exercise | A | 9.02 | 20,000 | 180,400 | 20,000 | ||
| May 29 2019 | ELOX | Eloxx Pharmaceutic ... | Pontifax Management 4 G.P. (20 ... | Option Exercise | A | 9.02 | 20,000 | 180,400 | 20,000 | ||
| Jun 19 2018 | ELOX | Eloxx Pharmaceutic ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Option Exercise | A | 23.27 | 40,000 | 930,800 | 40,000 | |
| Jun 19 2018 | ELOX | Eloxx Pharmaceutic ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Option Exercise | A | 23.27 | 40,000 | 930,800 | 40,000 | |
| May 01 2018 | ELOX | Eloxx Pharmaceutic ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | P | 9.75 | 93,333 | 909,997 | 520,396 | 427.1 K to 520.4 K (+21.85 %) |
| May 01 2018 | ELOX | Eloxx Pharmaceutic ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | P | 9.75 | 172,626 | 1,683,104 | 962,504 | 789.9 K to 962.5 K (+21.85 %) |
| May 01 2018 | ELOX | Eloxx Pharmaceutic ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | P | 9.75 | 84,041 | 819,400 | 468,585 | 384.5 K to 468.6 K (+21.85 %) |
| Mar 23 2018 | ELOX | Eloxx Pharmaceutic ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | P | 8.00 | 1,600 | 12,800 | 427,063 | 425.5 K to 427.1 K (+0.38 %) |
| Mar 23 2018 | ELOX | Eloxx Pharmaceutic ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | P | 8.00 | 2,959 | 23,672 | 789,878 | 786.9 K to 789.9 K (+0.38 %) |
| Mar 23 2018 | ELOX | Eloxx Pharmaceutic ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | P | 8.00 | 1,441 | 11,528 | 384,544 | 383.1 K to 384.5 K (+0.38 %) |
| Mar 23 2018 | ELOX | Eloxx Pharmaceutic ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | P | 7.55 | 1,760 | 13,288 | 425,463 | 423.7 K to 425.5 K (+0.42 %) |
| Mar 23 2018 | ELOX | Eloxx Pharmaceutic ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | P | 7.55 | 3,255 | 24,575 | 786,919 | 783.7 K to 786.9 K (+0.42 %) |
| Mar 23 2018 | ELOX | Eloxx Pharmaceutic ... | Pontifax Management 4 G.P. (20 ... | 10% Owner | Buy | P | 7.55 | 1,585 | 11,967 | 383,103 | 381.5 K to 383.1 K (+0.42 %) |
Page: 1